Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 2/20 | 0.48 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.46 |
| ▸ | BRD4 | O60885 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.42 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.40 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.40 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4293106 | 0.80 | PDE3B (0.47) | PDE3BPDE3AHSD17B10KDM4EALDH1A1 | |
| SCHEMBL4069762 | 0.77 | CFTR (0.47) | PDE3BPDE3AHSD17B10KDM4EALDH1A1 | |
| SCHEMBL10812441 | 0.75 | PDE3B (0.43) | PDE3BPDE3AHSD17B10BRD4CA12 | |
| SCHEMBL13726378 | 0.73 | HPGDS (0.45) | PDE3BPDE3AHSD17B10HPGDKDM4E | |
| SCHEMBL18014941 | 0.70 | ALKBH5 (0.49) | HSD17B10HPGDKDM4EALDH1A1GAA | |
| SCHEMBL11608488 | 0.69 | HPGD (0.53) | HSD17B10HPGDKDM4EALDH1A1GAA | |
| SCHEMBL11100168 | 0.67 | PDE3B (0.53) | PDE3BPDE3AHSD17B10HPGDKDM4E | |
| SCHEMBL4904481 | 0.66 | NQO2 (0.41) | PDE3BPDE3AKDM4ENQO2KMT2A | |
| SCHEMBL27659542 | 0.66 | BRD4 (0.47) | BRD4KDM4EALDH1A1ADORA1ADORA2A | |
| SCHEMBL8944339 | 0.65 | BRPF1 (0.63) | HSD17B10BRD4CA12BRPF1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1596860-A4 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2009-05-27 | — | — | EP | claimed |
| US-20060211727-A1 | Novel compounds | GLAXOSMITHKLINE LLC | 2006-09-21 | — | — | US | claimed |
| EP-1596860-A2 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-11-23 | — | — | EP | claimed |
| WO-2004073628-A2 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-09-02 | — | — | WO | claimed |
| US-20090239897-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239897-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239897-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-7550480-B2 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550480-B2 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550480-B2 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-23 | — | — | US | disclosed |
| EP-1596860-A4 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20060211727-A1 | Novel compounds | GLAXOSMITHKLINE LLC | 2006-09-21 | — | — | US | disclosed |
| EP-1596860-A2 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-11-23 | — | — | EP | disclosed |
| WO-2004073628-A2 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-09-02 | — | — | WO | disclosed |
| EP-0168037-B1 | 1-6-NAPHTHYRIDIN-2(1H)-ONES USEFUL AS CARDIOTONICS | STERLING DRUG INC. (US) | 1990-02-07 | — | — | EP | disclosed |
| EP-0168037-A2 | 1-6-Naphthyridin-2(1H)-ones useful as cardiotonics | STERLING DRUG INC. (US) | 1986-01-15 | — | — | EP | disclosed |
| US-4560691-A | 5-(Phenyl)-1,6-naphthyridin-2(1H)-ones, their cardiotonic use and preparation | STERLING DRUG INC. (US) | 1985-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239897-A1 | NOVEL COMPOUNDS | MAPKAPK2, CREBBP, MAPK1 | PDE3B 965/4885PDE3A 1294/4885HSD17B10 3181/4885 |
| US-20060211727-A1 | Novel compounds | MAPKAPK2, CREBBP, MAPK1 | PDE3B 965/4885PDE3A 1294/4885HSD17B10 3181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.